Companies/Lobe Sciences Ltd.

Company profile

Lobe Sciences Ltd.

OTC: LOBEF · Healthcare · Drug Manufacturers - Specialty & Generic

Canadian filerHQ Vancouver, BCReports USD

#1143 of 1,394 Healthcare companies by revenuebottom-decile growth

EA Score

42D

FH 45DQ —GM 43SS 20

v0.1 · 45/100 weight · provisional

↑ growth stability, balance-sheet leverage · ↓ revenue growth (YoY), listing tenure

Methodology →

Revenue TTM

Rev growth YoY (TTM)

needs 8 qtrs

Net income (FY)

-$3.2M

Employees

—

Market cap

$1.4M

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Revenue$00 CAD2025

Net income-$3.2M-4.4M CAD2025

Operating income-$3.0M-4.2M CAD2025

Total assets$5.5M7.6M CAD2025

Liabilities$2.0M2.7M CAD2025

Equity$1.7M2.4M CAD2025

Revenue trend

FY2018 – FY2025 · USD

FY18

$583.8k

FY19

$657.5k

FY20

FY21

FY22

$624.1k

FY23

$100.1k

FY24

FY25

Revenue by segment

No segmentation disclosed for this filer. n/a

The read

Lobe Sciences Ltd. booked $0 in FY2025 revenue, contracting 100% year over year — among the slowest-growing Healthcare companies we track, at a -Infinity% net margin.

Peers · Healthcare

Escalon Medical Corp.63C 60 Degrees Pharmaceuticals, Inc.34D North American Cannabis Holdings, Inc.——Oncology Pharma Inc.——

Key facts

CEOFrederick Dominick Sancilio

SectorHealthcare

IndustryDrug Manufacturers - Specialty & Generic

HeadquartersVancouver, BC

ExchangeOTC: LOBEF

Employees—

IPO date2023-08-24

Latest filings

No filings loaded — no CIK (non-SEC filer).

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.